- 米国企業
- IONIS PHARMACEUTICALS INC
IONIS PHARMACEUTICALS INCIONS
| 2010年
12月31日 | 2011年
12月31日 | 2012年
12月31日 | 2013年
12月31日 | 2014年
12月31日 | 2015年
12月31日 | 2016年
12月31日 | 2017年
12月31日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 | 2023年
12月31日 |
|---|
| Net loss | -61 | -85 | -65 | -61 | -39 | - | - | -17 | 215 | 303 | -487 | -29 | -270 | - |
|---|
| Net loss | -61 | -85 | -65 | -61 | -39 | -88 | -87 | -6 | 274 | 303 | -451 | -29 | -270 | -366 |
|---|
| Depreciation | 5 | 7 | 7 | 7 | 6 | 7 | 7 | 7 | 11 | 13 | 13 | 15 | 14 | 10 |
|---|
| Amortization of right-of-use operating lease assets | - | - | - | - | - | - | - | - | - | - | 2 | 2 | 5 | 10 |
|---|
| Amortization of other assets | - | - | - | - | - | - | - | - | 2 | 2 | 2 | 2 | 2 | 3 |
|---|
| Amortization of premium (discount) on investments, net | - | - | - | - | - | -8 | -7 | -7 | 1 | 7 | -12 | -18 | -7 | 29 |
|---|
| Amortization of debt issuance costs | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 5 | 5 | 6 |
|---|
| Stock-based compensation expense | 12 | 10 | 9 | 11 | 31 | 59 | 72 | 86 | 131 | 147 | 230 | 121 | 100 | 106 |
|---|
| The amount of royalty payments made during the period under a royalty purchase agreement. | - | - | - | - | - | - | - | - | - | - | - | - | - | 45 |
|---|
| 0.125 percent convertible senior notes due December 2024. | - | - | - | - | - | - | - | - | - | - | - | - | - | 13 |
|---|
| Loss (gain) on early retirement of debt | - | - | -5 | - | -8 | - | -4 | - | - | -22 | - | -9 | - | 13 |
|---|
| Amount of interest expense using the effective interest rate method related to the sale of future royalties. | - | - | - | - | - | - | - | - | - | - | - | - | - | 68 |
|---|
| Non-cash losses related to disposal of property, plant and equipment | - | - | - | - | - | - | - | - | - | - | - | - | -1 | -17 |
|---|
| Stock-based compensation expense | 12 | 10 | 9 | 11 | 31 | 59 | 72 | 86 | 131 | 147 | 230 | 121 | 100 | 106 |
|---|
| Gain on sale of real estate assets | - | - | - | - | - | - | - | - | - | - | - | - | 150 | -0 |
|---|
| 0.125 percent convertible senior notes due December 2024. | - | - | - | - | - | - | - | - | - | - | - | - | - | 13 |
|---|
| Loss (gain) on early retirement of debt | - | - | -5 | - | -8 | - | -4 | - | - | -22 | - | -9 | - | 13 |
|---|
| Loss (gain) on investments | - | - | - | - | - | - | - | - | - | - | - | 1 | -0 | -2 |
|---|
| Non-cash losses related to disposal of property, plant and equipment | - | - | - | - | - | - | - | - | - | - | - | - | -1 | -17 |
|---|
| Deferred income taxes, including changes in valuation allowance | - | - | - | - | - | - | - | - | -291 | -7 | 313 | - | - | - |
|---|
| Gain on sale of real estate assets | - | - | - | - | - | - | - | - | - | - | - | - | 150 | -0 |
|---|
| Non-cash losses related to other assets | - | - | - | - | - | - | - | - | - | - | 2 | 3 | 2 | 2 |
|---|
| Loss (gain) on investments | - | - | - | - | - | - | - | - | - | - | - | 1 | -0 | -2 |
|---|
| Contracts receivable | - | - | - | - | - | - | - | - | -48 | 48 | 13 | -14 | -36 | 72 |
|---|
| Inventories | -0 | 2 | 2 | 2 | -2 | 1 | 1 | 2 | -1 | 5 | 1 | 3 | -3 | 6 |
|---|
| Other current and long-term assets | 1 | -1 | -0 | 1 | 2 | 4 | -2 | 58 | 29 | 45 | 10 | 1 | 25 | 30 |
|---|
| The increase (decrease) during the reporting period in income taxes receivable (payable), which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid or the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. | - | - | - | - | - | - | - | - | - | - | - | -1 | - | - |
|---|
| Accounts payable | 1 | 1 | 1 | 0 | 5 | 9 | -11 | 2 | -1 | -16 | -3 | -6 | 1 | 8 |
|---|
| Accounts payable | 1 | 1 | 1 | 0 | 5 | 9 | -11 | 2 | -1 | -16 | -3 | -6 | 1 | 8 |
|---|
| Income taxes | - | - | - | - | -4 | - | 1 | 0 | -1 | 32 | -31 | -1 | 6 | -4 |
|---|
| Income taxes | - | - | - | - | -4 | - | 1 | 0 | -1 | 32 | -31 | -1 | 6 | -4 |
|---|
| Accrued compensation | 0 | 2 | -1 | 4 | 0 | 4 | 8 | 1 | 4 | 8 | 28 | -27 | 10 | 19 |
|---|
| Accrued compensation | 0 | 2 | -1 | 4 | 0 | 4 | 8 | 1 | 4 | 8 | 28 | -27 | 10 | 19 |
|---|
| Accrued liabilities and other current liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | -6 |
|---|
| Accrued liabilities and other current liabilities | - | - | - | - | - | - | - | - | - | - | - | -8 | 47 | - |
|---|
| Deferred contract revenue | - | - | - | - | - | - | - | - | 494 | -119 | -76 | -83 | -71 | 14 |
|---|
| Deferred contract revenue | - | - | - | - | - | - | - | - | 494 | -119 | -76 | -83 | -71 | 14 |
|---|
| Non-cash losses related to other assets | - | - | - | - | - | - | - | - | - | - | 2 | 3 | 2 | 2 |
|---|
| Contracts receivable | - | - | - | - | - | - | - | - | -48 | 48 | 13 | -14 | -36 | 72 |
|---|
| Inventories | -0 | 2 | 2 | 2 | -2 | 1 | 1 | 2 | -1 | 5 | 1 | 3 | -3 | 6 |
|---|
| Other current and long-term assets | 1 | -1 | -0 | 1 | 2 | 4 | -2 | 58 | 29 | 45 | 10 | 1 | 25 | 30 |
|---|
| The increase (decrease) during the reporting period in income taxes receivable (payable), which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid or the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. | - | - | - | - | - | - | - | - | - | - | - | -1 | - | - |
|---|
| Accounts payable | 1 | 1 | 1 | 0 | 5 | 9 | -11 | 2 | -1 | -16 | -3 | -6 | 1 | 8 |
|---|
| Accounts payable | 1 | 1 | 1 | 0 | 5 | 9 | -11 | 2 | -1 | -16 | -3 | -6 | 1 | 8 |
|---|
| Income taxes | - | - | - | - | -4 | - | 1 | 0 | -1 | 32 | -31 | -1 | 6 | -4 |
|---|
| Income taxes | - | - | - | - | -4 | - | 1 | 0 | -1 | 32 | -31 | -1 | 6 | -4 |
|---|
| Accrued compensation | 0 | 2 | -1 | 4 | 0 | 4 | 8 | 1 | 4 | 8 | 28 | -27 | 10 | 19 |
|---|
| Accrued compensation | 0 | 2 | -1 | 4 | 0 | 4 | 8 | 1 | 4 | 8 | 28 | -27 | 10 | 19 |
|---|
| Accrued liabilities and other current liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | -6 |
|---|
| Accrued liabilities and other current liabilities | - | - | - | - | - | - | - | - | - | - | - | -8 | 47 | - |
|---|
| Deferred contract revenue | - | - | - | - | - | - | - | - | 494 | -119 | -76 | -83 | -71 | 14 |
|---|
| Deferred contract revenue | - | - | - | - | - | - | - | - | 494 | -119 | -76 | -83 | -71 | 14 |
|---|
| Net cash provided by (used in) operating activities | -64 | -115 | - | - | - | - | - | 174 | 603 | 346 | 36 | 31 | -274 | -308 |
|---|
| Net loss | -61 | -85 | -65 | -61 | -39 | - | - | -17 | 215 | 303 | -487 | -29 | -270 | - |
|---|
| Net loss | -61 | -85 | -65 | -61 | -39 | -88 | -87 | -6 | 274 | 303 | -451 | -29 | -270 | -366 |
|---|
| Depreciation | 5 | 7 | 7 | 7 | 6 | 7 | 7 | 7 | 11 | 13 | 13 | 15 | 14 | 10 |
|---|
| Amortization of right-of-use operating lease assets | - | - | - | - | - | - | - | - | - | - | 2 | 2 | 5 | 10 |
|---|
| Amortization of other assets | - | - | - | - | - | - | - | - | 2 | 2 | 2 | 2 | 2 | 3 |
|---|
| Amortization of premium (discount) on investments, net | - | - | - | - | - | -8 | -7 | -7 | 1 | 7 | -12 | -18 | -7 | 29 |
|---|
| Amortization of debt issuance costs | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 5 | 5 | 6 |
|---|
| Stock-based compensation expense | 12 | 10 | 9 | 11 | 31 | 59 | 72 | 86 | 131 | 147 | 230 | 121 | 100 | 106 |
|---|
| The amount of royalty payments made during the period under a royalty purchase agreement. | - | - | - | - | - | - | - | - | - | - | - | - | - | 45 |
|---|
| 0.125 percent convertible senior notes due December 2024. | - | - | - | - | - | - | - | - | - | - | - | - | - | 13 |
|---|
| Loss (gain) on early retirement of debt | - | - | -5 | - | -8 | - | -4 | - | - | -22 | - | -9 | - | 13 |
|---|
| Amount of interest expense using the effective interest rate method related to the sale of future royalties. | - | - | - | - | - | - | - | - | - | - | - | - | - | 68 |
|---|
| Non-cash losses related to disposal of property, plant and equipment | - | - | - | - | - | - | - | - | - | - | - | - | -1 | -17 |
|---|
| Stock-based compensation expense | 12 | 10 | 9 | 11 | 31 | 59 | 72 | 86 | 131 | 147 | 230 | 121 | 100 | 106 |
|---|
| Gain on sale of real estate assets | - | - | - | - | - | - | - | - | - | - | - | - | 150 | -0 |
|---|
| 0.125 percent convertible senior notes due December 2024. | - | - | - | - | - | - | - | - | - | - | - | - | - | 13 |
|---|
| Loss (gain) on early retirement of debt | - | - | -5 | - | -8 | - | -4 | - | - | -22 | - | -9 | - | 13 |
|---|
| Loss (gain) on investments | - | - | - | - | - | - | - | - | - | - | - | 1 | -0 | -2 |
|---|
| Non-cash losses related to disposal of property, plant and equipment | - | - | - | - | - | - | - | - | - | - | - | - | -1 | -17 |
|---|
| Deferred income taxes, including changes in valuation allowance | - | - | - | - | - | - | - | - | -291 | -7 | 313 | - | - | - |
|---|
| Gain on sale of real estate assets | - | - | - | - | - | - | - | - | - | - | - | - | 150 | -0 |
|---|
| Non-cash losses related to other assets | - | - | - | - | - | - | - | - | - | - | 2 | 3 | 2 | 2 |
|---|
| Loss (gain) on investments | - | - | - | - | - | - | - | - | - | - | - | 1 | -0 | -2 |
|---|
| Contracts receivable | - | - | - | - | - | - | - | - | -48 | 48 | 13 | -14 | -36 | 72 |
|---|
| Inventories | -0 | 2 | 2 | 2 | -2 | 1 | 1 | 2 | -1 | 5 | 1 | 3 | -3 | 6 |
|---|
| Other current and long-term assets | 1 | -1 | -0 | 1 | 2 | 4 | -2 | 58 | 29 | 45 | 10 | 1 | 25 | 30 |
|---|
| The increase (decrease) during the reporting period in income taxes receivable (payable), which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid or the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. | - | - | - | - | - | - | - | - | - | - | - | -1 | - | - |
|---|
| Accounts payable | 1 | 1 | 1 | 0 | 5 | 9 | -11 | 2 | -1 | -16 | -3 | -6 | 1 | 8 |
|---|
| Accounts payable | 1 | 1 | 1 | 0 | 5 | 9 | -11 | 2 | -1 | -16 | -3 | -6 | 1 | 8 |
|---|
| Income taxes | - | - | - | - | -4 | - | 1 | 0 | -1 | 32 | -31 | -1 | 6 | -4 |
|---|
| Income taxes | - | - | - | - | -4 | - | 1 | 0 | -1 | 32 | -31 | -1 | 6 | -4 |
|---|
| Accrued compensation | 0 | 2 | -1 | 4 | 0 | 4 | 8 | 1 | 4 | 8 | 28 | -27 | 10 | 19 |
|---|
| Accrued compensation | 0 | 2 | -1 | 4 | 0 | 4 | 8 | 1 | 4 | 8 | 28 | -27 | 10 | 19 |
|---|
| Accrued liabilities and other current liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | -6 |
|---|
| Accrued liabilities and other current liabilities | - | - | - | - | - | - | - | - | - | - | - | -8 | 47 | - |
|---|
| Deferred contract revenue | - | - | - | - | - | - | - | - | 494 | -119 | -76 | -83 | -71 | 14 |
|---|
| Deferred contract revenue | - | - | - | - | - | - | - | - | 494 | -119 | -76 | -83 | -71 | 14 |
|---|
| Non-cash losses related to other assets | - | - | - | - | - | - | - | - | - | - | 2 | 3 | 2 | 2 |
|---|
| Contracts receivable | - | - | - | - | - | - | - | - | -48 | 48 | 13 | -14 | -36 | 72 |
|---|
| Inventories | -0 | 2 | 2 | 2 | -2 | 1 | 1 | 2 | -1 | 5 | 1 | 3 | -3 | 6 |
|---|
| Other current and long-term assets | 1 | -1 | -0 | 1 | 2 | 4 | -2 | 58 | 29 | 45 | 10 | 1 | 25 | 30 |
|---|
| The increase (decrease) during the reporting period in income taxes receivable (payable), which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid or the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. | - | - | - | - | - | - | - | - | - | - | - | -1 | - | - |
|---|
| Accounts payable | 1 | 1 | 1 | 0 | 5 | 9 | -11 | 2 | -1 | -16 | -3 | -6 | 1 | 8 |
|---|
| Accounts payable | 1 | 1 | 1 | 0 | 5 | 9 | -11 | 2 | -1 | -16 | -3 | -6 | 1 | 8 |
|---|
| Income taxes | - | - | - | - | -4 | - | 1 | 0 | -1 | 32 | -31 | -1 | 6 | -4 |
|---|
| Income taxes | - | - | - | - | -4 | - | 1 | 0 | -1 | 32 | -31 | -1 | 6 | -4 |
|---|
| Accrued compensation | 0 | 2 | -1 | 4 | 0 | 4 | 8 | 1 | 4 | 8 | 28 | -27 | 10 | 19 |
|---|
| Accrued compensation | 0 | 2 | -1 | 4 | 0 | 4 | 8 | 1 | 4 | 8 | 28 | -27 | 10 | 19 |
|---|
| Accrued liabilities and other current liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | -6 |
|---|
| Accrued liabilities and other current liabilities | - | - | - | - | - | - | - | - | - | - | - | -8 | 47 | - |
|---|
| Deferred contract revenue | - | - | - | - | - | - | - | - | 494 | -119 | -76 | -83 | -71 | 14 |
|---|
| Deferred contract revenue | - | - | - | - | - | - | - | - | 494 | -119 | -76 | -83 | -71 | 14 |
|---|
| Net cash provided by (used in) operating activities | -64 | -115 | - | - | - | - | - | 174 | 603 | 346 | 36 | 31 | -274 | -308 |
|---|
| Purchases of short-term investments | - | 371 | 218 | 426 | 392 | 493 | 301 | 878 | 1,795 | 1,947 | 1,570 | 1,124 | 1,486 | 1,771 |
|---|
| Proceeds from sale of short-term investments | - | 489 | 243 | 173 | 295 | 420 | 365 | 557 | 883 | 1,952 | 1,886 | 1,344 | 989 | 1,585 |
|---|
| Purchases of property, plant and equipment | 13 | 7 | 1 | 2 | 8 | 8 | 7 | 35 | 14 | 31 | 35 | 12 | 16 | 24 |
|---|
| Proceeds from sale of real estate assets | 0 | - | - | - | - | - | - | - | - | - | - | - | 254 | 0 |
|---|
| Acquisition of licenses and other assets, net | - | - | - | - | - | - | - | - | - | - | - | 6 | 4 | 4 |
|---|
| Purchases of strategic investments | - | - | - | - | - | - | - | - | - | - | - | 7 | - | - |
|---|
| Net cash provided by (used in) investing activities | 24 | 111 | - | - | - | - | - | -358 | -930 | -41 | 274 | 195 | -263 | -214 |
|---|
| Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases | 4 | 4 | 9 | 63 | 23 | 25 | - | 23 | 28 | 120 | 52 | 12 | 6 | 49 |
|---|
| Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options | - | - | - | - | - | - | - | - | - | 19 | 13 | 17 | 11 | - |
|---|
| 1.75 percent convertible senior notes due June 2028. | - | - | - | - | - | - | - | - | - | - | - | - | - | 575 |
|---|
| 0 percent convertible senior notes due April 2026. | - | - | - | - | - | - | - | - | - | - | - | 633 | - | - |
|---|
| 1 percent convertible senior notes due November 2021. | - | - | - | - | 487 | - | - | - | - | - | - | - | - | - |
|---|
| Proceeds from issuance of convertible senior notes | - | - | 195 | - | - | - | - | - | - | 110 | - | - | - | - |
|---|
| The cash outflow paid to third parties in connection with a monetization transaction of future SPINRAZA and pelacarsen royalties the Company is entitled to under collaboration and licensing agreements. | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - |
|---|
| 1.75 percent convertible senior notes due June 2028. | - | - | - | - | - | - | - | - | - | - | - | - | - | 14 |
|---|
| 0 percent convertible senior notes due April 2026. | - | - | - | - | - | - | - | - | - | - | - | 16 | - | - |
|---|
| Convertible senior notes issuance costs | - | - | - | - | - | - | - | - | - | 10 | - | - | - | - |
|---|
| 1.75 percent convertible senior notes due June 2028. | - | - | - | - | - | - | - | - | - | - | - | - | - | 14 |
|---|
| 0 percent convertible senior notes due April 2026. | - | - | - | - | - | - | - | - | - | - | - | 16 | - | - |
|---|
| Convertible senior notes issuance costs | - | - | - | - | - | - | - | - | - | 10 | - | - | - | - |
|---|
| The cash outflow from the extinguishment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. | - | - | - | - | - | - | - | - | - | - | - | - | - | 488 |
|---|
| The cash outflow from the extinguishment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. | - | - | - | - | - | - | - | - | - | - | - | - | - | 488 |
|---|
| The cash inflow from the sale of future royalties under a royalty purchase agreement. | - | - | - | - | - | - | - | - | - | - | - | - | - | 500 |
|---|
| Repayment of remaining principal amount of 1 percent convertible senior notes at maturity | - | - | - | - | - | - | - | - | - | - | - | - | - | 504 |
|---|
| The cash outflow paid to third parties for transaction costs in connection with a monetization transaction of future SPINRAZA and pelacarsen royalties the Company is entitled to under collaboration and licensing agreements. | - | - | - | - | - | - | - | - | - | - | - | - | - | 10 |
|---|
| Proceeds from issuance of warrants | - | - | - | - | - | - | - | - | - | 56 | - | 90 | - | - |
|---|
| The cash inflow from the transfer of legal ownership of two lots of undeveloped land to a real estate investor. | - | - | - | - | - | - | - | - | - | - | - | - | - | 32 |
|---|
| Purchase of note hedges | - | - | - | - | - | - | - | - | - | 109 | - | 137 | - | - |
|---|
| Repayment of remaining principal amount of 1 percent convertible senior notes at maturity | - | - | - | - | - | - | - | - | - | - | - | - | - | 504 |
|---|
| Repurchases and retirements of common stock | - | - | - | - | - | - | - | - | - | 34 | 91 | - | - | - |
|---|
| Proceeds from issuance of warrants | - | - | - | - | - | - | - | - | - | 56 | - | 90 | - | - |
|---|
| Principal payments on debt | - | - | - | - | - | - | - | - | - | - | - | - | 51 | 0 |
|---|
| Purchase of note hedges | - | - | - | - | - | - | - | - | - | 109 | - | 137 | - | - |
|---|
| Purchase of noncontrolling interest of Akcea Therapeutics, Inc., including cash payments for cancellation of Akcea Therapeutics, Inc. equity awards | - | - | - | - | - | - | - | - | - | - | 545 | - | - | - |
|---|
| Principal payments on debt | - | - | - | - | - | - | - | - | - | - | - | - | 51 | 0 |
|---|
| Net cash provided by (used in) financing activities | 5 | -1 | - | - | - | - | - | 229 | 476 | 100 | -597 | 246 | -55 | 644 |
|---|
| Effects of exchange rates on cash | - | - | - | - | - | - | - | - | - | - | - | - | -0 | 0 |
|---|
| Net increase (decrease) in cash and cash equivalents | - | - | - | - | - | - | - | - | - | - | -286 | 472 | -593 | 123 |
|---|
| Interest paid | 5 | - | - | - | - | - | - | 8 | 10 | 10 | 6 | 5 | 3 | 7 |
|---|
| Income taxes paid | - | - | - | - | - | - | - | - | - | - | - | 0 | 5 | 48 |
|---|
| Right-of-use assets obtained in exchange for lease liabilities | - | - | - | - | - | - | - | - | - | 14 | 2 | 7 | 169 | - |
|---|
| Future cash outflow to pay for purchases of fixed assets and patents that have been incurred. | - | - | - | - | - | 1 | 3 | 2 | 4 | 3 | 4 | 1 | 5 | 0 |
|---|
| Purchases of short-term investments | - | 371 | 218 | 426 | 392 | 493 | 301 | 878 | 1,795 | 1,947 | 1,570 | 1,124 | 1,486 | 1,771 |
|---|
| Proceeds from sale of short-term investments | - | 489 | 243 | 173 | 295 | 420 | 365 | 557 | 883 | 1,952 | 1,886 | 1,344 | 989 | 1,585 |
|---|
| Purchases of property, plant and equipment | 13 | 7 | 1 | 2 | 8 | 8 | 7 | 35 | 14 | 31 | 35 | 12 | 16 | 24 |
|---|
| Proceeds from sale of real estate assets | 0 | - | - | - | - | - | - | - | - | - | - | - | 254 | 0 |
|---|
| Acquisition of licenses and other assets, net | - | - | - | - | - | - | - | - | - | - | - | 6 | 4 | 4 |
|---|
| Purchases of strategic investments | - | - | - | - | - | - | - | - | - | - | - | 7 | - | - |
|---|
| Net cash provided by (used in) investing activities | 24 | 111 | - | - | - | - | - | -358 | -930 | -41 | 274 | 195 | -263 | -214 |
|---|
| Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases | 4 | 4 | 9 | 63 | 23 | 25 | - | 23 | 28 | 120 | 52 | 12 | 6 | 49 |
|---|
| Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options | - | - | - | - | - | - | - | - | - | 19 | 13 | 17 | 11 | - |
|---|
| 1.75 percent convertible senior notes due June 2028. | - | - | - | - | - | - | - | - | - | - | - | - | - | 575 |
|---|
| 0 percent convertible senior notes due April 2026. | - | - | - | - | - | - | - | - | - | - | - | 633 | - | - |
|---|
| 1 percent convertible senior notes due November 2021. | - | - | - | - | 487 | - | - | - | - | - | - | - | - | - |
|---|
| Proceeds from issuance of convertible senior notes | - | - | 195 | - | - | - | - | - | - | 110 | - | - | - | - |
|---|
| The cash outflow paid to third parties in connection with a monetization transaction of future SPINRAZA and pelacarsen royalties the Company is entitled to under collaboration and licensing agreements. | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - |
|---|
| 1.75 percent convertible senior notes due June 2028. | - | - | - | - | - | - | - | - | - | - | - | - | - | 14 |
|---|
| 0 percent convertible senior notes due April 2026. | - | - | - | - | - | - | - | - | - | - | - | 16 | - | - |
|---|
| Convertible senior notes issuance costs | - | - | - | - | - | - | - | - | - | 10 | - | - | - | - |
|---|
| 1.75 percent convertible senior notes due June 2028. | - | - | - | - | - | - | - | - | - | - | - | - | - | 14 |
|---|
| 0 percent convertible senior notes due April 2026. | - | - | - | - | - | - | - | - | - | - | - | 16 | - | - |
|---|
| Convertible senior notes issuance costs | - | - | - | - | - | - | - | - | - | 10 | - | - | - | - |
|---|
| The cash outflow from the extinguishment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. | - | - | - | - | - | - | - | - | - | - | - | - | - | 488 |
|---|
| The cash outflow from the extinguishment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. | - | - | - | - | - | - | - | - | - | - | - | - | - | 488 |
|---|
| The cash inflow from the sale of future royalties under a royalty purchase agreement. | - | - | - | - | - | - | - | - | - | - | - | - | - | 500 |
|---|
| Repayment of remaining principal amount of 1 percent convertible senior notes at maturity | - | - | - | - | - | - | - | - | - | - | - | - | - | 504 |
|---|
| The cash outflow paid to third parties for transaction costs in connection with a monetization transaction of future SPINRAZA and pelacarsen royalties the Company is entitled to under collaboration and licensing agreements. | - | - | - | - | - | - | - | - | - | - | - | - | - | 10 |
|---|
| Proceeds from issuance of warrants | - | - | - | - | - | - | - | - | - | 56 | - | 90 | - | - |
|---|
| The cash inflow from the transfer of legal ownership of two lots of undeveloped land to a real estate investor. | - | - | - | - | - | - | - | - | - | - | - | - | - | 32 |
|---|
| Purchase of note hedges | - | - | - | - | - | - | - | - | - | 109 | - | 137 | - | - |
|---|
| Repayment of remaining principal amount of 1 percent convertible senior notes at maturity | - | - | - | - | - | - | - | - | - | - | - | - | - | 504 |
|---|
| Repurchases and retirements of common stock | - | - | - | - | - | - | - | - | - | 34 | 91 | - | - | - |
|---|
| Proceeds from issuance of warrants | - | - | - | - | - | - | - | - | - | 56 | - | 90 | - | - |
|---|
| Principal payments on debt | - | - | - | - | - | - | - | - | - | - | - | - | 51 | 0 |
|---|
| Purchase of note hedges | - | - | - | - | - | - | - | - | - | 109 | - | 137 | - | - |
|---|
| Purchase of noncontrolling interest of Akcea Therapeutics, Inc., including cash payments for cancellation of Akcea Therapeutics, Inc. equity awards | - | - | - | - | - | - | - | - | - | - | 545 | - | - | - |
|---|
| Principal payments on debt | - | - | - | - | - | - | - | - | - | - | - | - | 51 | 0 |
|---|
| Net cash provided by (used in) financing activities | 5 | -1 | - | - | - | - | - | 229 | 476 | 100 | -597 | 246 | -55 | 644 |
|---|
| Effects of exchange rates on cash | - | - | - | - | - | - | - | - | - | - | - | - | -0 | 0 |
|---|
| Net increase (decrease) in cash and cash equivalents | - | - | - | - | - | - | - | - | - | - | -286 | 472 | -593 | 123 |
|---|
| Interest paid | 5 | - | - | - | - | - | - | 8 | 10 | 10 | 6 | 5 | 3 | 7 |
|---|
| Income taxes paid | - | - | - | - | - | - | - | - | - | - | - | 0 | 5 | 48 |
|---|
| Right-of-use assets obtained in exchange for lease liabilities | - | - | - | - | - | - | - | - | - | 14 | 2 | 7 | 169 | - |
|---|
| Future cash outflow to pay for purchases of fixed assets and patents that have been incurred. | - | - | - | - | - | 1 | 3 | 2 | 4 | 3 | 4 | 1 | 5 | 0 |
|---|